Are the effects of statins on HDL-cholesterol clinically relevant?
M.J. Chapman* National Institute for Health and Medical Research (INSERM), Unit 551, Hôpital de la Pitié, Paris Cedex 13, France * Correspondence: National Institute for Health and Medical Research, Hôpital de la Pitié, 83, boulevard de l’hôpital, 75651 Paris Cedex 13, France. Tel./fax: +33-1-45-82-81-98 chapman{at}chups.jussieu.fr’ + u + ‘@’ + d + ”//–> Abstract It has been established that the level of plasma high-density lipoprotein (HDL)-cholesterol is inversely proportional to the risk of coronary heart disease (CHD). HDL particles are highly heterogeneous, particularly in terms of their biological activities, many of which are atheroprotective. For example, in addition to carrying out reverse cholesterol transport, HDL protects the vascular endothelium by inhibiting monocyte adhesion and the oxidative modification of low-density lipoprotein (LDL), eliminates some of the atherogenic products of LDL oxidation, and possesses antithrombotic activity, due to the inhibition of platel
